RESUMO
The aim of this study is to determine whether the addition of mitoxantrone to high dose cytarabine improves the outcome of treatment in patients with relapsed or refractory acute myeloid leukemia (AML). One hundred and sixty-two eligible patients, 14-76 years of age, with AML either in first relapse or that failed to respond to initial remission induction therapy, with no CNS involvement were randomized to receive therapy with cytarabine 3 gm/M2 i.v. over 2 h every 12 h for 12 doses on days 1-6 (Arm I) (HIDAC); or HIDAC plus mitoxantrone 10 mg/M2 i.v. daily on days 7 9 (Arm II) (HIDAC + M). Patients achieving complete remission were treated with three courses of consolidation including HIDAC (Ara-C 3 gm/M2 i.v. 12 h days 1 3; 2 gm/M2 over age 50) alone (ARM I) or with mitoxantrone (10 mg/M2 i.v. day 1) (ARM II). Among 162 patients (81 HIDAC, 81 HIDAC + M) evaluated for induction toxicity, there were 10 (12%) induction deaths with HIDAC and 13 (17%) with HIDAC + M (2-tailed P = 0.65). Most early deaths were due to infection and/or hemorrhage. Among 162 patients evaluated for responses to induction therapy, 26/81 (32%) HIDAC and 36/81 (44%) HIDAC + M patients achieved complete remission (two-tailed P = 0.15). Although this difference was not statistically significant in univariate analysis, it was after adjusting for the effects of WBC and PMN percentage in multivariate analysis (P=0.013). Median survivals from study entry were 8 months (HIDAC) and 6 months (HIDAC + M); 2-tailed logrank P = 0.58. Among 48 patients registered for consolidation, the median disease-free survivals from that registration were 8 months with HIDAC and 11 months with HIDAC + M (P = 0.60). There were three treatment-related deaths during consolidation (1 HIDAC, 2 HIDAC + M), all due to infections. In this randomized trial, the addition of mitoxantrone to high-dose cytarabine was associated with a trend toward a higher CR rate. There was less evidence for an advantage in disease-free or overall survival, although any such conclusion is limited by the size of the study.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Mieloide/tratamento farmacológico , Doença Aguda , Adolescente , Adulto , Idoso , Citarabina/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mitoxantrona/administração & dosagem , Prognóstico , Recidiva , Resultado do TratamentoRESUMO
We describe a 49-year-old woman with a history of metastatic renal cell carcinoma and classic signs and symptoms of left-sided cavernous sinus syndrome. Magnetic resonance imaging showed a lesion in the left cavernous sinus consistent with metastatic renal cell carcinoma. The patient received radiation therapy totaling 4,600 cGy, with complete resolution of symptoms. This represents the first case report of renal cell carcinoma metastatic to the left cavernous sinus.
Assuntos
Neoplasias Encefálicas/secundário , Carcinoma de Células Renais/secundário , Seio Cavernoso , Neoplasias Renais/diagnóstico , Imageamento por Ressonância Magnética , Neoplasias Vasculares/secundário , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/radioterapia , Carcinoma de Células Renais/diagnóstico , Carcinoma de Células Renais/radioterapia , Seio Cavernoso/patologia , Irradiação Craniana , Feminino , Humanos , Neoplasias Renais/radioterapia , Pessoa de Meia-Idade , Síndrome , Resultado do Tratamento , Neoplasias Vasculares/diagnóstico , Neoplasias Vasculares/radioterapiaRESUMO
Fourteen participating centers registered 33 patients on a Southwest Oncology Group Study of adults with acute non-lymphocytic leukemia (ANLL). Induction consisted of cytosine arabinoside 70 mg/m2 days 1-7 by continuous intravenous (i.v.) infusion, VP-16 50 mg/m2 i.v. over 1 hour days 1-3, and daunomycin 30 mg/m2 i.v. bolus days 1-3. Twenty-five patients (median age 69 years) were evaluable for response. Eleven (44%) achieved a remission marrow but only 8 fulfilled both blood and marrow criteria for complete remission. Of the 11 patients with a remission marrow, there were no patients over 70 years of age. Major coexisting disease data were evaluated. Only 5 patients had no major coexisting disease and 4 of those 5 achieved a remission marrow. The study illustrates and underscores the following problems of remission induction in the elderly: (a) increased susceptibility to the stress of the induction period, with 6 patients (24%) dying before treatment day sixteen; (b) disease resistance to antileukemic therapy with persistent ANLL in 6 patients (24%), despite two induction courses; and (c) hematopoietic stem cell sensitivity in the elderly with marrow regeneration failure documented in 2 patients (8%) following induction. Acute nonlymphocytic leukemia in the elderly has a poor prognosis, and novel therapeutic approaches are warranted.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Leucemia Mieloide Aguda/tratamento farmacológico , Idoso , Exame de Medula Óssea , Citarabina/administração & dosagem , Daunorrubicina/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Resultado do TratamentoRESUMO
Clinical faculty commonly acknowledge that they have difficulty evaluating third- and fourth-year medical students. The faculty and administration of the Louisiana State University (LSU) School of Medicine in New Orleans conducted pilot tests of two types of materials to assess these problems as part of the Clinical Evaluation Program undertaken by the Association of American Medical Colleges in 1984-1985. The two types of materials--questionnaires and the Problem-Case Analysis--were developed by the staff of the AAMC program and used by the LSU Department of Medicine and the Department of Obstetrics and Gynecology to identify problems in the process of evaluating clerks. Furthermore, the two methods proved complementary: both methods identified some of the same problems and each identified problems not identified by the other. Handling difficult students was the single problem identified by both methods in both departments. The questionnaires permit a simple method of collecting data about a broad range of problems. The Problem-Case Analysis, on the other hand, requires more time but evokes possible causes and alternative solutions, as well as identifying the problems. Improvement plans were developed by each department to address the problems that surfaced.
Assuntos
Educação de Graduação em Medicina , Avaliação Educacional/métodos , Estudos de Avaliação como Assunto , Louisiana , Projetos Piloto , Inquéritos e QuestionáriosRESUMO
The Southwest Oncology Group did a limited institutional pilot study of the combination of doxorubicin and ifosfamide in the treatment of previously treated adult patients with acute leukemia. Thirty-four patients received one or two courses of the combination. All patients had received prior chemotherapy and 32 had received prior anthracycline chemotherapy. Three patients died before their responses could be fully evaluated. Fourteen patients achieved complete remission (41%) and one patient achieved partial remission. The complete remission rate was 27% for patients with acute myeloblastic leukemia (myelomonoblastic leukemia, monoblastic leukemia, and erythroleukemia) and 89% for patients with acute lymphocytic and undifferentiated leukemia (ALL). Toxic effects included severe hematologic reactions in 33 of 34 patients, hematuria in six patients, altered sensorium in one patient, and congestive heart failure in one patient. The safety of the combination was established and toxic side effects of this therapy were tolerable. The 89% complete remission rate for previously treated patients with ALL suggests that the combination of doxorubicin and ifosfamide may be particularly effective in ALL.